Insider buying last 90 days
No open-market insider purchases were filed for SNDX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SNDX insider filing, plotted on the chart in Gekko.Open SNDX in Gekko
NASDAQ: SNDX
Syndax Pharmaceuticals (SNDX) Stock Analysis & Forecast
Oct 12 close
$16.55−0.44 (−2.6%)
Gekko Brief
AI summaryOct 12 closeThis week’s news flow centers on clinical and analyst developments rather than financial results. Syndax announced topline results from the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis, which did not meet its primary endpoint of annualized rate of FVC decline, though the drug was described as well tolerated with a safety profile comparable to placebo and no new safety signals. Axatilimab continues to advance in multiple cGVHD trials, with results expected later this year and into early 2028. Separately, Syndax received a "Moderate Buy" consensus rating from eleven analysts, with an average 12-month price target of $41.80, and the company also granted 213,300 inducement options to new employees.
Shares closed at $16.55, down 2.6% on the day, sitting below both the 50-day moving average of $18.95 and the 200-day average of $20.76, with the 50-day below the 200-day. The GekkoIndex reads 66.2, placing the stock in the Accumulation zone. Price sits 28.3% below Gekko Fair Value of $23.08.
Earnings are scheduled for 2 November 2026, 21 days away, falling within a typical 20-trading-day holding window; the prior quarter saw revenue of $115 million from Revuforj and Niktimvo combined, with an EPS miss against estimate. Seasonality over the past 5 years shows an average 20-day return of 4.2% from this point, rising in 2 of those years. No insider, Congress, or unusual options activity appears in the current window. Consensus among 10 covering firms stands entirely at Buy, with a target of $37.55.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Syndax Pharmaceuticals price vs fair value
Close $16.55200-day averageGekko Fair Value $23.08
Syndax Pharmaceuticals quick facts
- Market cap
- $1.47B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.52
- Revenue, TTM
- $252.3M
- Profit margin
- -87.5%
- Dividend yield
- —
- Beta
- 0.42
- Volume
- 1.84M avg 1.94M
- 1-year return
- +2.2%
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±9.7%
- 50-day average
- $18.95
- 200-day average
- $20.76
- Next earnings
- Nov 2
- Shares outstanding
- 89.30M
Syndax Pharmaceuticals swing-trade checklist
Syndax Pharmaceuticals scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $16.55 is below the 50-day ($18.95) and 200-day ($20.76) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
66.2, Accumulation
Reading 66.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
28.3% below
Price is 28.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 21 days
Reports on Nov 2, 2026, 21 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+4.2% on average
From this point in the calendar, the next 20 trading days averaged +4.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Syndax Pharmaceuticals stock chart and price history
Syndax Pharmaceuticals closed at $16.55 on Oct 12, 2026, +2.2% over the past year, inside a 52-week range of $12.99 to $25.59.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.0%
- 3 months
- −31.4%
- 6 months
- −31.8%
- 1 year
- +2.2%
The full SNDX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SNDX in Gekko
Follow Syndax Pharmaceuticals through every session
Put SNDX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SNDX in GekkoFree for 7 days. No credit card required.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biopharmaceutical business whose work centers on experimental cancer treatments that have not yet reached the market. Its most advanced project, SNDX-5613, is being tested in a Phase 1/2 trial to see whether blocking the Menin and MLL1 protein interaction can help patients with MLL-rearranged leukemia or NPM1 mutant acute myeloid leukemia. A separate candidate, axatilimab, also called SNDX-6352, is an antibody built to interfere with the CSF-1 receptor and is being explored as a possible option for chronic graft versus host disease. A third compound under study is entinostat.
Much of this research moves forward through outside ties rather than independent effort alone. Syndax works with the National Cancer Institute on research and development, coordinates trial work through an agreement with the Eastern Cooperative Oncology Group, and has licensed related technology from Kyowa Hakko Kirin Co., Ltd.
The company dates back to 2005 and runs its operations out of Waltham, Massachusetts. Investors can find its stock listed on the NASDAQ under the ticker SNDX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- syndax.com
Syndax Pharmaceuticals GekkoIndex: the smart money zone
Syndax Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.2, in the Accumulation zone, up 3.5 points over five sessions.
66.2Accumulation
Up 3.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | +1.4% | +5.2% | ||
| Accumulation (current zone) | 260 | +0.3% | +2.2% | ||
| Neutral | 337 | −0.1% | −0.8% | ||
| Distribution | 36 | +0.1% | −2.0% | ||
| Selling | 1 | Too few readings yet | |||
Average SNDX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the SNDX price, zone by zone.Track SNDX in Gekko
Is Syndax Pharmaceuticals stock overvalued? Gekko Fair Value
Syndax Pharmaceuticals trades 28.3% below Gekko Fair Value of $23.08, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Syndax Pharmaceuticals shares are worth, recalculated every trading day.
$23.08
Gekko Fair Value, Oct 10, 2026
28.3% Undervalued
At the end of Aug 2026 the price was 22.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SNDX in Gekko
Syndax Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Syndax Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SNDX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SNDX, plotted on the chart in Gekko.Open SNDX in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds SNDX.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Syndax Pharmaceuticals earnings: next date and track record
Syndax Pharmaceuticals reports on Nov 2, 2026 (21 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 2, 2026
21 days away
- EPS estimate
- −$0.48
- Revenue estimate
- $82.41M
5 of 8reports beat the EPS estimate
±12.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Syndax reported Q2 2026 combined net revenue of $115 million from Revuforj and Niktimvo. Revuforj generated $55 million (+91% YoY, +12% QoQ) driven by menin inhibition leadership and increasing treatment duration. Niktimvo reached $60 million (+67% YoY) with strong chronic GVHD adoption in 3rd and 4th line. Pipeline catalysts include frontline AML pivotal trials and NUP98 data expected in Q4.
- Guidance
- Management expects Revuforj to exceed $2 billion peak annual U.S. net revenue with frontline AML approval. Both products are annualizing above $200 million each. Phase II data in IPF and frontline chronic GVHD expected Q4 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.55 est −$0.45 | $72.79M est $79.37M | +3.5% |
| Apr 30, 2026 | −$0.48 est −$0.59 | $64.86M est $69.76M | −7.4% |
| Feb 26, 2026 | −$0.78 est −$0.58 | $68.73M est $64.30M | +4.6% |
| Nov 3, 2025 | −$0.70 est −$0.74 | $45.87M est $63.34M | +12.0% |
| Aug 4, 2025 | −$0.83 est −$1.00 | $37.96M est $45.65M | +26.0% |
| May 5, 2025 | −$0.98 est −$1.04 | $20.04M est $18.55M | −22.5% |
| Mar 3, 2025 | −$1.10 est −$1.08 | $7.68M est $12.79M | −8.1% |
| Nov 5, 2024 | −$0.98 est −$1.11 | $12.50M est $115.2M | +12.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Syndax Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Syndax Pharmaceuticals is $37.55, +126.9% from the last close, from 10 firms rating the stock in the last 90 days.
$37.55consensus 12-month target, +126.9% from the last close
Now $16.55Avg $37.55
Low $26High $57
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | H.C. Wainwright | $38 | +129.6% |
| Oct 1 | H.C. Wainwright | $38 | +129.6% |
| Sep 29 | Citi | $57 | +244.4% |
| Sep 21 | H.C. Wainwright | $38 | +129.6% |
| Aug 21 | UBS | $33 | +99.4% |
+2.2%average 20-day move after past Accumulation readings
+4.2%average move over the next 20 trading days in the last 5 years
±4.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Syndax Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Syndax Pharmaceuticals averaged +4.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | 0.0% | 3 of 5 |
| Next 10 trading days | −3.2% | 2 of 5 |
| Next 15 trading days | +1.7% | 3 of 5 |
| Next 20 trading days | +4.2% | 2 of 5 |
| Next 30 trading days | +2.0% | 3 of 5 |
For scale, SNDX’s typical 20-trading-day move in either direction is about 9.7%.
Syndax Pharmaceuticals market cap and key statistics
Syndax Pharmaceuticals’s market cap is $1.47B and revenue of $252.3M over the last twelve months.
Valuation
- Market cap
- $1.47B
- EPS, TTM
- −$2.52
- Gekko Fair Value
- $23.08
Trading
- Volume
- 1.84M
- Avg volume, 20 days
- 1.94M
- 52-week high
- $25.59
- 52-week low
- $12.99
- Shares outstanding
- 89.30M
Financials
- Revenue, TTM
- $252.3M
- Profit margin
- -87.5%
- Return on equity
- -255.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.42
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±9.7%
Syndax Pharmaceuticals stock news this week
Coverage of Syndax Pharmaceuticals this week reads neutral: 1 positive, 2 neutral and 0 negative headlines.
- Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary FibrosisGlobeNewsWire, Oct 12
- Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical ComparisonDefense World, Oct 12
- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsMarketBeat, Oct 9
- Syndax Pharmaceuticals Q3 2026 Earnings Date and EstimatesMarketBeat, Oct 7
- Syndax grants 213,300 options: 10 analysts rate Syndax Pharmaceuticals stock BuyAD HOC NEWS, Oct 6
Syndax Pharmaceuticals peers
Syndax Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Syndax Pharmaceuticals stock FAQ
What is Syndax Pharmaceuticals’s market cap?
Syndax Pharmaceuticals’s market cap is $1.47B at the Oct 12, 2026 close of $16.55, with 89.30M shares outstanding.
What is the Syndax Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Syndax Pharmaceuticals is $37.55, +126.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Syndax Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Syndax Pharmaceuticals is undervalued: the Oct 12, 2026 close of $16.55 is 28.3% below Gekko Fair Value of $23.08. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Syndax Pharmaceuticals report earnings next?
Syndax Pharmaceuticals is expected to report on Nov 2, 2026 (21 days away). Analysts expect earnings of −$0.48 per share on revenue of $82.41M. Syndax Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 12.1% on average across the report.
What is Syndax Pharmaceuticals’s 52-week high and low?
Syndax Pharmaceuticals’s 52-week high is $25.59 and its 52-week low is $12.99; it closed at $16.55 on Oct 12, 2026, +2.2% over the past year. Over the last five years the shares peaked at $29.86 on Feb 2, 2023.
Is Syndax Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Syndax Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.